RaNA Therapeutics snaps up $55 mln
Cambridge, Massachusetts-based RaNA Therapeutics, a RNA-focused drug developer, has closed $55 million in Series B funding. MRL Ventures and the Baupost Group LLC led the round with participation from other investors that included Rock Springs Capital Management, Brookside Capital, Leerink Partners LLC, Atlas Venture, Monsanto, MS Ventures, Omega Funds, Partners Innovation Fund, Pfizer Venture Investments and SR One. In addition to the funding, Dr. Joshua Resnick, president of MRL Ventures, has been added to RaNA's board of directors.
23 July 2015•3 mins read
